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rpf PCBs have caused elevated liver enzyme levels and chloracne in humans, and
'--'----- may have reproductive effects.
&  PCBs cause cancer in animals and may be carcinogenic in humans.
lEf PCBs are environmentally persistent and concentrate upward in the food chain.
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How to use this issue...
This issue begins with a composite case study that describes a realistic encounter with a patient. This description 
is followed by a pretest. The case study is further developed through Challenge questions at the end of each 
section. To fully benefit from this monograph, readers are urged to answer each question when it is presented. 
(Answers to the Pretest and Challenge questions are found on pages 15 and 16.) The monograph ends with a 
posttest which can be submitted to ATSDR for continuing medical education (CME) credit or continuing education 
units (CEU). See page 17 for further instructions on how to receive these credits.
The objectives of this monograph on PCBs are to help you:
□  Explain why PCBs are an acute and chronic health hazard
□  Describe the known factors contributing to PCB toxicity
□  Identify potential environmental or occupational sources of exposure to PCBs
□  Identify evaluation and treatment protocols for persons exposed to PCBs









Treatment and Management.................. 12




Posttest and Credits................................ 17
This issue is prepared with the assistance of those who share a common concern for physician education, public 
health, and the environment, including the following organizations: American Academy of Family Physicians 
(AAFP), American Academy of Pediatrics (AAP), American College of Emergency Physicians (ACEP), American 
College of Occupational and Environmental Medicine (ACOEM), American Medical Association (AMA), Associa­
tion of State and Territorial Health Officials (ASTHO), and the Society of Teachers of Family Medicine (STFM). 
Final responsibility for the contents and views expressed in this monograph resides with ATSDR.
Agency for Toxic Substances and Disease Registry 
Project Officers: Max Lum, EdD, and Donna Orti, MS 
Prepared by 
DeLima Associates, San Rafael, California, 
under Contract No. 205-88-0636
Case Study




A 48-year-old handyman with progressive cystic acne and abnormal liver function
You have been treating a 48-year-old man conservatively for his facial acne vulgaris. He first sought 
treatment about 3 months ago, remarking that such blemishes are typical for a teenager but he never had 
them during adolescence. Therapy was initiated with benzoyl peroxide washes and topical antibiotics, in 
addition to instructions for skin hygiene. When no real improvement was noted, oral antibiotics were 
prescribed. Due to continued lack of efficacy, this regimen was later supplemented by Retin-A™* (tretinoin) 
cream.
The patient has returned for a follow-up visit and complains that the acne is worse. On examination, you 
agree, and tell the patient you would like to refer him to a dermatologist for Accutane™* (isotretinoin) 
therapy. A serum biochemical and hematologic profile are ordered to document baseline values before 
therapy begins.
To your surprise, the biochemical panel reveals the following abnormalities: total bilirubin 2.8 mg/dL 
(normal 0-1.5), direct bilirubin 0.4 mg/dL (normal 0-0.4), SGPT (ALT) 74 IU/L (normal 0-50), SGOT (AST) 
88 IU/L (normal 0-50), GGPT (GGT) 190 IU/L (normal 15-85), LDH 230 IU/L (normal 50-225). Other testing, 
including complete blood count, alkaline phosphatase, BUN, creatinine, and urinalysis are within normal 
limits.
On questioning, the patient denies history of hepatitis, contact with hepatitis patients, other liver difficulties 
or blood transfusion. He informs you he has Gilbert’s syndrome and has had elevated bilirubin levels in the 
past. There is no family history of cardiovascular disease or cancer. The patient does not smoke; he drinks 
2 to 3 bottles of beer each evening, and sometimes more on weekends. He is currently taking no 
medications other than those mentioned. Review of systems is otherwise unremarkable.
Social history reveals the patient is married with three teenaged children; his wife and children are in good 
health. They live in a high-rise apartment building where the patient has been handyman and part-time 
building manager for the last year. He spends much time in the basement area, which includes a workshop, 
recreation room with pool table, and laundry and heating facilities. An avid fisherman, he spends most 
weekends fishing in Lake Michigan with his two sons. Physical examination reveals mild, nontender 
hepatomegaly without jaundice. His acne, which is most prominent on the upper face lateral to the 
eyebrows, began about 8 months ago.
* Use of trade names is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department 
of Health and Human Services.
iPretest
(a) What should be included in the patient’s problem list?
(b) What is a differential diagnosis for the patient’s altered liver enzymes?
(c) What tests would be useful in helping you arrive at a diagnosis?
Answers to the Pretest can be found on page 15.




PCBs persist in the environ­
ment, concentrating upward 
in the food chain.
The primary nonoccupational 
source of PCB exposure is 
food, especially fish from 
contaminated water.
Polychlorinated biphenyls (PCBs) are a family of 209 chemicals 
with varying numbers of chlorine atoms attached in varying 
positions to two connected benzene rings (Figure 1). Commer­
cial PCB products are always mixtures of PCBs and are usually 
contaminated with small amounts of polychlorinated dibenzofu- 
rans (furans) or polychlorinated dibenzodioxins (dioxins). Con­
tamination by furans is a concern because their toxicity is 
generally much greater than that of PCBs.
Figure 1. Polychlorinated biphenyls and related compounds
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X = Chlorine or Hydrogen
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PCB Toxicity
Because of their insulating and nonflammable properties, PCBs 
have been used as heat exchange and dielectric fluids in trans­
formers and capacitors, hydraulic and lubricating fluids, diffusion 
pump oils, plasticizers, extenders for pesticides, and as ingredi­
ents of caulking compounds, paints, adhesives, and flame retar­
dants. PCBs have also been used in inks and carbonless paper. 
Trade names for PCBs include Aroclor, Askarel, Eucarel, Pyranol, 
Dykanol, Clorphen, Asbestol, Diaclor, Nepolin, and EEC-18.*
PCB mixtures are colorless to dark brown oils, viscous liquids, or 
sticky resinous semi-solids. They evaporate slowly at room 
temperature; however, their volatility increases dramatically 
with small increases in temperature. Overheated equipment that 
contains PCBs can vaporize significant quantities of these com­
pounds, causing an inhalation hazard, especially in areas where 
ventilation is poor.
Today PCBs are found mainly in transformers and capacitors 
manufactured before the U.S. Environmental Protection Agency 
(EPA) banned the production of PCBs in 1977. Many of these old 
transformers and capacitors are still contained in industrial 
equipment (such as welding equipment), medical equipment 
(such as X-ray machines), and household appliances (such as 
refrigerators). Ballasts of fluorescent light fixtures may contain 
PCBs. During normal lighting operation, the PCBs are entirely 
enclosed; however, when the capacitor wears out, it may burn or 
break and leak PCBs.
PCBs can be released into the general environment from poorly 
maintained toxic waste sites; by illegal or improper dumping of 
PCB wastes, such as transformerfluids; through leaks or fugitive 
emissions from electrical transformers containing PCBs; and by 
disposal of PCB-containing consumer products in municipal 
landfills. PCBs have been found in at least 271 of 1177 hazardous 
waste sites on the EPA National Priorities List. Of the 1.25 billion 
pounds of PCBs produced in this country since 1929, about 450 
million pounds have found their way into the environment. The 
chemical stability of these synthetic compounds accounts for 
their persistence in the environment. Another important reason 
for their persistence is their resistance to biodégradation.
Low levels of PCBs can be found throughout the world. PCBs in 
water or on soil surfaces evaporate and return to earth by rainfall 
or settling of dust particles. Because PCBs strongly adsorb to 
soil particles, significant leaching from soil and translocation to 
plants do not occur. Although PCBs are widespread in the
* Use of trade names is for identification only and does not imply endorsement 




aquatic environment, their low water solubility helps to prevent 
high concentrations in drinking water supplies.
Food can be a major source of PCB exposure, usually from fish 
and animal fat. PCBs are lipophilic; they preferentially separate 
from water and adsorb to sediment. Bottom feeders and other 
aquatic organisms then ingest and accumulate PCBs, resulting 
in bioconcentration upward in the food chain. Composite analy­
sis of commercial whole fish collected from Lake Ontario in 1980 
found PCB levels of 0.11 to 4.90 parts per million (ppm).
The toxicity of PCBs was dramatically illustrated in 1968 when 
over 1600 people in Japan were poisoned by cooking oil con­
taminated with PCBs from a heat transfer unit. The contaminat­
ing oil likely contained furans and dioxins, compounds generally 
more toxic than PCBs themselves. The ensuing illnesses be­
came known as “Yusho” (rice oil disease).
(1) Additional information for the case study: In response to your persistent, detailed questioning 
regarding his hobbies and possible contact with hepatotoxins, the patient reveals that while 
in the basement workshop he frequently wipes up a “dark, oily discharge” near a large 
electrical transformer in the work area. The discharge has also resulted in a gummy residue 
on tools and other surfaces. He mentions he sometimes feels dizzy and nauseated after 
working in the basement all day.




Although PCBs are no longer manufactured in the United States, □  
the greatest potential for exposure to PCBs still occurs in the 
workplace. For example, workers may inhale or have dermal 
contact with PCBs during repair or maintenance of process 
equipment or electrical transformers and during accidents or _  
spills involving PCBs. Exposure can also occur in disposal of 
PCB-containing materials at hazardous waste sites. Occupa­
tions entailing risk of PCB exposure include, but are not limited 
to, the following:




hazardous waste hauling/site operating








Nonoccupational exposures have also occurred. The public has 
encountered PCBs through illegal roadside dumping of hazard­
ous waste oils and through inhalation of smoke and soot from 
transformer or capacitor fires. Pyrolysis of PCBs can produce 
dioxins and furans, placing smoke-inhalation victims at increased 
risk of exposure to these toxic compounds.
Fetuses and neonates are potentially more sensitive to PCBs 
than adults because of transplacental distribution and physiol­
ogic differences. They lack the hepatic microsomal enzyme 
systems that facilitate metabolism and excretion of PCBs. Fur­
thermore, PCBs accumulate in breast milk. Nursing infants are 
at additional risk because human milk contains a steroid that 
inhibits PCB glucuronidation and excretion.
Other populations potentially more sensitive to PCBs are per­
sons with compromised hepatic functioning, including those with 
incompletely developed glucuronide conjugation mechanisms 
due to congenital disorders such as Gilbert’s syndrome, and 
persons with hepatic infections. Persons taking medications 
potentially toxic to the liver may also be at increased risk.
Certain workers can be 
exposed to PCBs during 
repair of equipment and 
accidents or spills.
Fetuses and neonates may be 
more sensitive to PCBs than 
adults; nursing infants are at 
increased risk of exposure 
from PCB-exposed mothers.
Persons with compromised 
hepatic function may metabo­
lize PCBs less efficiently than 
healthy persons.
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Chaikngê
(2) Are other sources o f PCB exposure likely for the patient described in the case study?
Biologic Fate
PCBs are readily absorbed into the body but slowly metabolized 
and excreted. After absorption, PCBs partition between the 
aqueous and lipid compartments of the body in a biphasic 
pattern. During the first day after PCBs were administered to 
laboratory animals, they were distributed mainly to the liver and 
muscle tissue. In a second phase, PCBs were redistributed to 
the adipose tissue, skin and other fat-containing organs. More 
highly chlorinated PCBs redistribute to adipose tissue to a 
greater extent than do PCBs with a lower percentage of chlorine; 
the presence of more highly chlorinated PCBs appears to delay 
excretion of the lesser chlorinated compounds for reasons not 
clearly understood.
The liver is the primary site of PCB metabolism by hydroxylation 
and conjugation with glucuronic acid and sulfates. The rate of 
metabolism depends on the number and position of chlorine 
atoms, with lesser chlorinated isomers being more readily me­
tabolized.
Excretion of PCBs is slow, so bioaccumulation occurs even at 
low exposure levels. As long as exposure continues, a true 
steady state is never achieved. PCBs metabolized with more 
difficulty are excreted almost exclusively by the biliary route; 
metabolites of PCBs with a smaller percentage of chlorination 
are eliminated through bile and urine. Urinary metabolites are in 
the form of conjugates, including glucuronides and sulfates.
There are essentially no pharmacokinetic data for humans. PCB 
half-lives in the rat range from 1 day to 460 days depending on 
the degree of chlorination.
□  PCBs are stored in lipid 
tissues.
□  The liver is the primary site 
of PCB metabolism.




Background levels in human sera are typically less than 20 parts 
per billion (ppb), and residues measured in human milk have 
ranged from 40 to 100 ppb. Reported levels in adipose tissue 
range from 1 to 2 ppm.
JChallenge
(3) Explain why patients with Gilbert’s syndrome may be at increased risk of adverse effects due to 
PCB exposure.
Physiologic Effects
In humans, PCB toxicity affects the skin and liver, and may have 
developmental effects. Metabolic, reproductive, endocrine, and 
immunosuppressive effects have been noted in animals, but 
have not been adequately studied in humans. Although data 
from animal studies indicate that PCBs are definitely animal 
carcinogens, data from PCB-exposed human populations are 
inconsistent and inconclusive.
□  PCBs have low potential to 
cause acute effects.




Chloracne is the only overt effect of PCB exposure in humans, 
but absence of chloracne does not rule out exposure. There is no 
reliable dose-response model for chloracne in exposed popula­
tions; the dose-response relationship may be dependent upon 
individual predisposition. Chloracne typically develops weeks or 
months after exposure. The lesions are often refractory to 
treatment and can last for years. One case persisted for more 
than 30 years.
□  PCB-induced chloracne can 
reflect systemic toxicity.
The acneform lesions arise from altered differentiation of acinar 
sebaceous base cells into keratinocytes. The chin, periorbital, 
and malar areas are affected most often, although lesions may
7
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□  High-level PCB exposure 
may produce elevated levels 
of liver enzymes.
□  Evidence suggests that 
PCBs cause hepatotoxicity 
in humans.
also appear on the chest, arms, thighs, genitalia, and buttocks- 
areas not commonly affected by acne vulgaris. The most 
distinctive lesions are cystic and measure from 1 to 10 millime­
ters (mm). Other prominent lesions are comedo. The cysts and 
comedones can become inflamed and secondarily infected. The 
papules and cysts may be surrounded by edema and erythema. 
Chloracne may result not only from dermal contact but also from 
ingestion and generally indicates systemic toxicity.
Besides chloracne, Yusho patients had hyperpigmentation of 
the skin, conjunctiva, gingiva, and nails. These pigmentation 
disturbances have also been noted in some PCB-exposed work­
ers.
Hepatic Effects
Epidemiologic studies and clinical surveys indicate that severe 
occupational exposure to PCBs can increase serum liver en­
zymes. The enzyme levels often show inconsistent patterns, 
however, and increases generally have not been associated with 
hepatic dysfunction, although approximately 10% of the Yusho 
patients experienced jaundice. Asymptomatic hepatomegaly 
has been reported in workers, many of whom had concomitant 
elevated serum PCB levels. Some researchers believe that 
aspartate aminotransferase (SGOT or AST) and gamma glutamyl 
transpeptidase (GGTP or GGT) are the most sensitive indicators 
of PCB exposure in humans, and that changes in these liver 
enzymes may occur at exposure levels below those at which 
chloracne appears. Liver damage, histologically documented, is 
the most consistent finding among laboratory animals tested 
with PCBs.
Increases in urinary porphyrin levels have been noted in a study 
of workers with low-level PCB exposure. Changes in porphyrin 
metabolism may be triggered by the induction of liver micro­
somal enzymes. PCBs are more potent enzyme inducers than 
phenobarbital, a drug that occasionally causes clinical problems 
due to its enzyme-inducing effects, and PCBs’ enzyme-inducing 
effects can persist long after cessation of exposure. The health 
implications for enzyme induction include the occurrence of 
disease secondary to increased metabolism of endogenous or 
exogenous substances, and interference in medical therapy due 
to increased metabolism of administered drugs.
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Reproductive and Developmental Effects
The Yusho incident documents PCBs’ potential to cause devel- □  PCBs have a potential to 
opmental and fetotoxic effects in humans. Two of the Yusho cause developmental and
mothers had stillbirths; 10 of 13 infants had abnormal skin fetotoxic effects in humans,
pigmentation, 9 of 13 had ocular discharge, and 12 of 13 were 
smaller than average. Two infants developed Yusho from breast 
feeding. In contrast, the authors of a study of nursing infants 
whose mothers were occupationally exposed to PCBs found no 
adverse health effects. Contaminants in the PCB oil cannot be 
ruled out as factors in Yusho disease. Follow-up of the Yusho 
infants revealed no persistent morphologic or behavioral abnor­
malities.
In laboratory animals, changes in estrous cycles, failure of ovum 
implantation, increased frequency of spontaneous abortions, 
and low birth weight of offspring have been reported after PCB 
exposure. No teratogenic effects have been reported in studies 
of humans or animals.
Carcinogenicity
The epidemiologic evidence is insufficient to evaluate the poten- □  PCBs are considered poten­
tial of PCBs as human carcinogens. Although Yusho victims tial human carcinogens on 
showed a slightly higher rate of deaths from neoplasms 15 years th® basis of results from 
after the incident, the data were not adjusted for age or smoking animal studies, 
and drinking patterns. Cancer data from other human popula­
tions are inconsistent and inconclusive.
Data from animal studies have shown that PCBs cause hepa- 
tocarcinomas, pituitary tumors, leukemia, lymphomas, and gas­
trointestinal tract tumors. On the basis of these data, EPA 
considers PCBs to be probable human carcinogens.
Challenge
(4) Is there a need to be concerned about PCB exposure when the clinical effects of the patient 
in the case study seem so limited?
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Clinical Evaluation
□  Chloracne is the only known 
overt sign of PCB toxicity; 
however, absence of 
chloracne does not rule out 
exposure.
□  Because of an EPA ban on 
PCB production in 1977, 
chronic exposure in the 
workplace is uncommon 
today.
History and Physical Examination
A detailed history will facilitate the diagnosis of chronic PCB 
poisoning. Pertinent information includes occupational histories 
of all household members, medications, and diet, including 
ethanol intake. During the physical examination, physicians 
should pay particular attention to the skin and hepatic system. 
Encountering a patient with PCB toxicity should trigger consid­
eration of whether this is a sentinel event, indicating the possi­
bility of other similarly exposed persons such as coworkers or 
family members.
Signs and Symptoms 
Acute Exposure
PCBs have very low potential for producing acute toxic effects. 
The only overt sign of PCB exposure is chloracne, which is 
described on page 7. Acneform lesions do not appear in all 
severely exposed patients (only 82% of Yusho patients had 
chloracne); therefore, its absence does not rule out exposure. 
New cases of chloracne should be reported to the local or state 
health department.
Elevated liver enzymes are the most sensitive effect of PCB 
exposure in animals and have been detected in several human 
epidemiologic studies. Hepatomegaly has also been noted in 
some PCB-exposed workers.
Chronic Exposure
Many people chronically exposed to PCBs have had no overt 
signs or symptoms of toxicity. In others, reported signs and 
symptoms of exposure with hepatic involvement have included 
weight loss, anorexia, nausea, vomiting, jaundice, and abdomi­
nal pain. The degree of liver injury was related to the degree of 
chlorination in the PCBs, dose and duration of exposure, and 
possible concurrent exposure to other hepatotoxins, infectious 
agents, or certain medications. Headache, dizziness, and edema 
have also been reported. Chronic PCB exposure in the work­





Some researchers believe that PCB blood levels after long-term 
exposure correlate well with adipose tissue levels. However, 
PCB analysis of either blood or adipose tissue is expensive and 
time-consuming and is not recommended unless exposure has 
been massive. Breast milk analysis for PCBs should not be 
considered unless the exposure is severe. PCBs detected in 
breast milk are not necessarily an indication that breast-feeding 
should be stopped.
Indirect Biologic Indicators
Liver function tests may be the most sensitive sign of PCB 
toxicity in the absence of chloracne; however, these measures 
are of questionable value because they are nonspecific. Also, 
normal liver enzyme values do not rule out significant exposure; 
body burden still may be elevated. PCB conjugates can often be 
detected in urine after exposure. Their analysis is expensive, 
unreliable, and not recommended.
Challenge
(5) What confirmatory laboratory test can be ordered to establish the diagnosis of PCB exposure?
(6) Additional information for the case study: The patient requests a serum PCB analysis. The 
laboratory reports a level o f 125 ppb, with no normal range indicated. How will you interpret this 
report?
Serum or adipose tissue PCB 
levels may indicate exposure, 
but they are difficult to 
interpret clinically.
Elevated liver-enzyme levels 
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□  There is no antidote for PCB 
exposure; treatment is 
symptomatic.
□  Removal from the source is 
the goal of treatment for PCB 
exposure.
Acute Exposure
In the event of PCB splashes in the eyes, irrigate with tepid water 
immediately for at least 15 minutes, and follow with ophthalmic 
evaluation. Remove contaminated clothing and discard prop­
erly. Gently wash affected skin with soap and warm water for at 
least 15 minutes.
In the rare event that PCB-containing substances are ingested, 
induce vomiting immediately if the patient is conscious. Gastric 
lavage may be subsequently administered at a medical facility 
until the gastric washings are clear. Activated charcoal has not 
been proven beneficial, but is not contraindicated. Exposed 
persons should have periodic follow-up examinations with par­
ticular attention to hepatic function and dermal lesions.
Chronic Exposure
There is no specific treatment for PCB toxicity. Diagnostic 
workup should be limited to liverfunction tests and dermatologic 
examination, with skin biopsy of lesions. Initial treatment of 
chloracne is based on cessation of exposure, good skin hygiene, 
and use of dermatologic measures commonly employed for acne 
vulgaris. If these measures are not efficacious, the patient 
should be referred to a dermatologist.
The carcinogenic potential of PCBs should be carefully reviewed 
with the patient, primarily to allay anxiety. Since there are no 
known methods of reducing reserves of PCBs in lipid tissues, 
attempts to purge the body of PCBs should not be undertaken. 
Saunas and nutritional therapies have no proven efficacy. Crash 
diets risk mobilizing PCBs stored in fat.
Since PCBs are hepatotoxins, history of exposure to other 
potentially hepatotoxic agents should be obtained and patients 
should be encouraged to avoid exposure to other hepatotoxins 
such as antibiotics or medications with known hepatotoxicity, 








The Occupational Safety and Health Administration's (OSHA) 
permissible exposure limit (PEL) is a time-weighted average 
(TWA) airborne concentration of 1000 (ig/m3 for PCBs contain­
ing 42% chlorine (average molecular formula of C12H7CI3). PCBs 
with 54% chlorine and an average molecular formula of C12H5CI5 
have a PEL of 500 (ig/m3. Both standards encompass all physical 
forms: aerosols, vapor, mist, sprays, and PCB-laden dust par­
ticles. OSHA considers that PCBs are absorbed through intact 
skin; therefore, dermal and inhalation exposure routes should 
be evaluated by an industrial hygienist.
The National Institute for Occupational Safety and Health (NIOSH) 
recommends a 10-hour TWA of 1 |o.g/m3 based on the minimum 
reliable detectable concentration and potential carcinogenicity 
of PCBs. NIOSH also recommends that all workplace exposures 
be reduced to the lowest feasible level.
Environment
Water
EPA considers PCBs a probable human carcinogen and prohib­
its industrial discharges under the Clean Water Act Effluent 
Guidelines. Currently, there is no legal maximum contaminant 
level for PCBs in drinking water. However, EPA advises that the
OSHA’s PEL is 1000 (xg/m3 
for PCBs containing no 
more than 42%  ch lo rin e , 
and 500 [¿g/m3 for com ­
pounds contain ing  up to 
54%  ch lorin e .
EPA does not have a 
standard  for PCBs in 
d rink ing  w ater.
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level of PCBs in drinking water be limited to 0.5 |ag/L on the basis 
of carcinogenicity at 10'4 to 10'6 risk levels.
Food
The Food and Drug Administration (FDA) mandates tolerances 
of 0.2 to 3.0 ppm PCBs for all foods, with a tolerance level in fish 
of 2 ppm. FDA also limits PCBs in plastic food-packaging 
materials to 10 ppm.
CfmHenge
(8) What regulatory steps should be taken for the situation described in the case study?
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Answers to Questions
Pretest
The pretest can be found on page 1.
(a) The patient’s problem list includes acne vulgaris, which is atypical because of the location of the lesions 
and their late onset without history of outbreaks during adolescence. The mildly altered liver functions 
are nonspecific in their interpretation and clinically unexpected. Gilbert’s syndrome is a hereditary, 
relatively common, benign, unconjugated hyperbilirubinemia. It may contribute to the laboratory 
findings of elevated bilirubin (especially after a fast) but would not explain the clinical picture or elevated 
liver enzymes.
(b) The combination of asymptomatic hepatomegaly and mild nonspecific elevations of hepatic enzymes 
in this case is suggestive of a chronic inflammatory liver process or hepatitis. The causes of hepatitis 
can be classified as drug-induced, toxic, infectious, genetic, and connective tissue disease-associated. 
The major cause of liver disease in the United States is alcohol ingestion. Less common are 
environmental exposures, resulting in either acute or chronic toxic hepatitis. Infectious hepatitides 
include those due to the viruses such as A (infectious), B (serum), C (transfusion-associated) and other 
possible agents of non-A, non-B hepatitis. Some connective tissue diseases such as lupus erythema­
tosus are associated with a specific type of hepatitis. Hepatitis may also occur with Epstein-Barr virus 
and cytomegalovirus infections.
Infiltrative diseases such as sarcoidosis or amyloidosis, and rare genetic diseases such as Wilson’s 
disease, primary hemochromatosis, and alpha^antitrypsin deficiency must be excluded.
(c) Viral serology and a heterophil antibody test should be considered. If there are suggestive signs or 
symptoms, a serum iron and total iron binding capacity, serum copper and ceruloplasmin, and 
antinuclear antibodies may be helpful. Assays for suspected hepatotoxins may also be of value. Further 




Challenge questions begin on page 4.
(1) Older electrical transformers and capacitors can contain PCBs as a dielectric and heat transfer fluid. 
Leaks in the equipment could allow PCBs to volatilize under conditions of increased temperature, such 
as those in a basement. A person with chronic exposure to the residue could eventually receive a 
significant PCB dose through both dermal and inhalation routes.
(2) Great Lakes fish, particularly from Lake Michigan, are known to be a potential source of PCBs. A 
correlation between consumption of PCB-contaminated fish and elevated serum PCB levels has been 
shown in a study of residents of New Bedford, Massachusetts. For the general population, however, a 
clinically significant human body burden of PCBs is unlikely to occur through fish consumption alone.
(3) Persons with Gilbert’s syndrome have decreased UDP-glucuronyltransferase activity, resulting in 
impaired glucuronidation of bilirubin and, presumably, of PCBs also. Since a PCB elimination pathway 
is excretion of the glucuronide in urine, impaired capacity to conjugate PCBs with glucuronic acid can 
theoretically lead to accumulated PCBs and greater body burden. This hypothesis has never been 
tested, however.
(4) Yes, it is important to be aware that potential carcinogenicity is the main reason PCB production was 
banned in the United States. Human evidence is still considered inadequate, but the animal evidence 
was strong enough for EPA, NIOSH, and IARC (the International Agency for Research on Cancer) to 
conclude that PCBs may have carcinogenic effects in humans.
(5) Selected laboratories have the capability to perform PCB analyses on human tissue. The lipophilic 
nature of PCBs causes them to accumulate in fat; consequently, analysis of adipose tissue obtained 
by biopsy has been advocated as a measure of long-term exposure. Serum PCB analysis, which is less 
invasive than fat biopsy, can also be done. However, such tests are expensive and health risks often 
cannot be determined from the results. Testing human tissue for PCB content, therefore, remains 
principally a research tool.
(6) A correlation between increasing levels of serum PCBs and dermatologic findings, including chloracne, 
has not been consistently found in human epidemiologic studies. However, one study involving 153 
workers with occupational exposure to PCBs showed 22 subjects with dermal abnormalities and a mean 
plasma PCB level of 87 ppb, while 131 subjects without abnormalities had a mean serum level of 
50 ppb. The difference was statistically significant. By comparison, plasma PCB levels in unexposed 
populations are less than 30 ppb. However, no serum PCB values are yet accepted as normal or toxic 
levels. Our patient’s PCB serum level of 125 ppb is nonetheless consistent with PCB exposure as an 
etiology for his unusual acne, and PCB exposure may be contributing to the hepatic effects noted.
(7) The first response is clearly to stop the exposure. In this case, the patient should stay away from the 
basement until the transformer is repaired and the basement area cleaned. He should also refrain from 
eating Great Lakes fish until his PCB level normalizes and the fish are known to be uncontaminated. 
Avoiding exposure is especially important, as there is no specific treatment for PCB accumulation. The 
need to avoid other hepatotoxic substances including alcohol should be stressed. Currently, there are 
no data to support monitoring serum PCB levels.
(8) Since cessation of exposure is of prime importance, the physician can be most helpful by specifically 
recommending proper abatement. In this case, the owner of the building should be notified of the 
potential health hazard. This may require the assistance of local, state, or federal agencies such as the 
department of public health and EPA. These agencies can work cooperatively with those involved to 
bring about remediation of the harmful exposure. It is important to prevent others from using the 




More information on the adverse effects of PCBs and the treatment and management of PCB-exposed 
persons can be obtained from ATSDR, your state and local health departments, and university medical 
centers. Case Studies in Environmental Medicine: Polychlorinated Biphenyl (PCB) Toxicity is one of a 
series. For other publications in this series, please use the order form on the back cover. For clinical 
inquiries, contact ATSDR, Division of Health Education, Office of the Director, at (404) 639-6204.
Posttest and Credits
Continuing education credit is available to health professionals who use this monograph and complete the 
posttest. The criterion for awarding continuing medical education (CME) credits and continuing education units 
(CEU) is a posttest score of 70% or better.
The Centers for Disease Control and Prevention (CDC) is accredited by the Accreditation Council for Continuing 
Medical Education (ACCME) to sponsor continuing medical education for physicians, and by the International 
Association for Continuing Education and Training (I ACET) to sponsor continuing education units for other health 
professionals.
The Agency for Toxic Substances and Disease Registry, in joint sponsorship with CDC, is offering 1 hour of CME 
credit in Category 1 of the Physician's Recognition Award of the American Medical Association and 0.1 hour of 
CEU for other health professionals upon completion of this monograph.
In addition, the series Case Studies in Environmental Medicine has been reviewed and is acceptable for credit 
by the following organizations:
The American Academy of Family Physicians (AAFP). This program has been reviewed and is acceptable for 
1 prescribed hour by the American Academy of Family Physicians. (Term of Approval: beginning January 1992.) 
For specific information, please consult the AAFP Office of Continuing Medical Education.
The American College of Emergency Physicians (ACEP). Approved by the American College of Emergency 
Physicians for one hour per issue of ACEP Category I credit.
The American Osteopathic Association (AOA). AOA has approved this issue for 1 credit hour of Category 
2-B credit.
The American Association of Occupational Health Nurses (AAOHN). AAOHN has approved this program for 
1.2 contact hours. Applicant will receive the assigned code number in the award letter.
The American Board of Industrial Hygiene (ABIH). ABIH has approved this program for 0.5 certification 
maintenance (CM) point per 3 Case Studies. The CM approval number is 2817.
To receive continuing education credit (CME or CEU), complete the Posttest on page 18 in the manner shown in 
the sample question below. Circle all correct answers.
Which of the following is known to precipitate migraine headaches?




After you have finished the Posttest, please transfer your answers to the answer sheet on the inside back cover 
and complete the evaluation on the lower half of that page. Fold, staple, and mail the back cover to Continuing 
Education Coordinator, Agency for Toxic Substances and Disease Registry, Division of Health Education, E33, 
1600 Clifton Road, Atlanta, GA 30333. Your confidential test score will be returned with an indication of where 
the correct answers can be found in the text. Validation of earned CME credit and CEUs will also be forwarded 
to participants, and their names, if requested, will be placed on the mailing list to receive other issues in the Case 
Studies in Environmental Medicine series.
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POSTTEST: POLYCHLORINATED BIPHENYLS (PCBs)
Circle all correct answers and transfer your answers to page 19.
1. Significant PCB exposure may occur from
a. eating fish from PCB-contaminated waters
b. exposure to leaking transformers
c. eating a vegetarian diet
d. inhaling soot or smoke from transformer or capacitor fires
e. drinking alcoholic beverages
2. Although little is currently understood about the biologic fate of PCBs in humans, what is known 
includes which of the following facts?
a. PCB excretion is slow
b. PCBs may bioaccumulate in adipose tissue
c. highly chlorinated PCBs may delay excretion of less highly chlorinated PCBs
d. the primary site of PCB metabolism is the liver
e. background levels of PCBs in serum are generally higher than those in adipose tissue or breast 
milk
3. Which of the following statements is (are) false?
a. chloracne can reflect systemic toxicity
b. liver enzymes are always elevated by PCBs
c. exposed populations have shown adverse developmental effects from PCBs
d. PCBs are known human carcinogens
e. a sensitive indication of PCB exposure in humans is cardiac dysfunction
4. PCBs have been considered carcinogenic because
a. they are associated with increased rates of hepatic cancer in humans
b. they are immunosuppressive in humans
c. they are associated with thymic atrophy in humans
d. they are associated with increased rates of many cancers in animals
e. (a) and (d)




d. elevated CPK isoenzymes
e. elevated liver enzymes
6. Signs of PCB toxicity by inhalation exposure may include
a. persistent chloracne and weight loss
b. ascites
c. abdominal discomfort
d. abnormal liver function
e. pancreatitis
7. In the treatment and management of PCB-exposed persons, you should
a. recommend that the patient avoid contact with other known hepatotoxins
b. administer mineral oil in response to acute ingestion
c. follow up with particular attention to hepatic function and dermal lesions
d. initially treat chloracne the same as you would acne vulgaris
e. place the patient on a crash diet to purge the body of PCBs
8. PCB-induced chloracne is characterized by
a. raised urticarial welts
b. septic patches with raised pustular furuncles
c. cystic papules and comedones
d. small grouped vesicles with regional lymph nodes enlarged
e. a distribution that may include the periorbital area, chest, and buttocks
18
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CASE STUDIES IN ENVIRONMENTAL MEDICINE: POLYCHLORINATED BIPHENYL TOXICITY
If you wish CME credits or CEUs, please indicate your answers to the Posttest questions on page 18 by circling 
the letters below for the correct answers. Complete the evaluation questionnaire and fill in the information 
requested on the reverse side. Tear off this last page, fold, staple, and mail to Continuing Education Coordinator, 
Agency for Toxic Substances and Disease Registry, Division of Health Education, E33,1600 Clifton Road, Atlanta, 
GA 30333.
1. a b c d e
2. a b c d e
3. a b c d e
4. a b c d e
5. a b c d e
6. a b c d e
7. a b c d e
8. a b c d e
Evaluation Questionnaire




DISAGREE DISAGREE DISAGREE AGREE
1. As a result of completing this monograph, I will be able to:
Explain why PCBs are an acute and chronic health hazard. 
Describe the known factors contributing to PCB toxicity.
Identify potential environmental or occupational sources of 
exposure to PCBs.
Identify evaluation and treatment protocols for persons exposed 
to PCBs.
List sources of information on PCBs.
2. The monograph addressed the objectives printed on the 
inside front cover.
3. I am more likely to ask patients questions regarding possible 
environmental exposures as a result of reading this issue.
4. Independent study was an effective teaching method for the content.
5. How much time (in minutes) was required to read this monograph 
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a Beryllium □ Lead Developmental Hazs
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□ Ethylene/Propylene Glycols
ML0993
stap le  o r tape
DEPARTMENT OF 
HEALTH & HUMAN SERVICES
Public Health Service 
Centers for Disease Control 
and Prevention (CDC)
Agency for Toxic Substances and Disease Registry 
Atlanta, GA 30333
Official Business
Penalty for Private Use $300
FIRST-CLASS MAIL 







The state of knowledge regarding the treatment of patients potentially exposed to 
hazardous substances in the environment is constantly evolving and is often 
uncertain. In this monograph, the Agency for Toxic Substances and Disease 
Registry (ATSDR) has made diligent effort to ensure the accuracy and currency 
of the information presented but makes no claim that the document comprehen­
sively addresses all possible situations related to this substance. This monograph 
is intended as an additional resource for physicians and other health professionals 
in assessing the condition and managing the treatment of patients potentially 
exposed to hazardous substances. It is not, however, a substitute for the 
professional judgment of a health care provider and must be interpreted in light 
of specific information regarding the patient available to such a professional and 
in conjunction with other sources of authority.
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